Alto Neuroscience reports FY2025 net loss $63.2M; cash $177M; ALTO-207 Phase 2b on track for 1H 2026

Alto Neuroscience, Inc.

Cash, cash equivalents & restricted cash $177M as of Dec 31, 2025; runway into 2028 covers four key readouts.
Net loss of $63.2M for FY2025 vs $61.4M in FY2024; R&D expenses $45.6M, G&A $20.7M.
Acquired ALTO-207 (pramipexole/ondansetron) for TRD; Lancet-published PAX-D study showed Cohen's d=0.87 effect size.
ALTO-207 Phase 2b trial expected to start 1H 2026, topline data 2H 2027; $50M PIPE completed in October 2025.
ALTO-101 granted FDA Fast Track for CIAS; Phase 2 POC topline data expected around end of Q1 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Alto Neuroscience, Inc. reported financial results for full year ended December 31, 2025.

Period: full year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 16, 2026, Alto Neuroscience, Inc. (the “Company”) reported financial results for the fiscal year ended December 31, 2025.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Alto Neuroscience, Inc. filing history →

Source: SEC EDGAR

accession 0001999480-26-000001

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.